- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
J. Safra Sarasin Holding AG Reduces AbbVie Stake
Institutional investor trims position in pharmaceutical giant by 10.4%
Mar. 31, 2026 at 9:53am
Got story updates? Submit your updates here. ›
A reduction in a major institutional investor's stake in AbbVie highlights the complex financial machinery underlying the pharmaceutical industry.North Chicago TodayJ. Safra Sarasin Holding AG, a Swiss financial services firm, lowered its position in shares of AbbVie Inc. (NYSE: ABBV) by 10.4% in the fourth quarter, according to a recent 13F filing with the Securities and Exchange Commission. The fund now owns 311,302 shares of the pharmaceutical company's stock, valued at $71.1 million.
Why it matters
AbbVie is a major holding for J. Safra Sarasin, accounting for 1.2% of its total portfolio. This reduction in the firm's AbbVie stake could signal a shift in its investment strategy or a broader reassessment of the pharmaceutical sector.
The details
According to the 13F filing, J. Safra Sarasin sold 36,172 shares of AbbVie during the fourth quarter. The firm's total position in the company is now valued at $71.1 million. AbbVie is the 20th largest holding in J. Safra Sarasin's investment portfolio.
- The 13F filing was submitted on March 31, 2026, covering the fourth quarter of 2025.
The players
J. Safra Sarasin Holding AG
A Swiss financial services firm that manages over $200 billion in assets for private and institutional clients.
AbbVie Inc.
A global biopharmaceutical company that develops and commercializes therapies for complex and chronic medical conditions.
The takeaway
This reduction in J. Safra Sarasin's AbbVie position could signal a broader shift in the firm's investment strategy or a reassessment of the pharmaceutical sector. However, AbbVie remains a significant holding, indicating the firm's continued confidence in the company's long-term prospects.
